Bank of America’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-606,106
| Closed | -$13.1M | – | 5785 |
|
|
2025
Q4 | $13.1M | Sell |
606,106
-732,636
| -55% | -$14.2M | ﹤0.01% | 2645 |
|
|
2025
Q3 | $20.4M | Buy |
1,338,742
+1,194,509
| +828% | +$15.5M | ﹤0.01% | 2603 |
|
|
2025
Q2 | $1.28M | Sell |
144,233
-973,857
| -87% | -$8.56M | ﹤0.01% | 5127 |
|
|
2025
Q1 | $8.75M | Buy |
1,118,090
+1,035,051
| +1,246% | +$8.67M | ﹤0.01% | 3272 |
|
|
2024
Q4 | $873K | Sell |
83,039
-399,433
| -83% | -$4.85M | ﹤0.01% | 5149 |
|
|
2024
Q3 | $6.33M | Sell |
482,472
-209,887
| -30% | -$3.2M | ﹤0.01% | 3513 |
|
|
2024
Q2 | $9.73M | Buy |
692,359
+656,884
| +1,852% | +$10.7M | ﹤0.01% | 2980 |
|
|
2024
Q1 | $599K | Buy |
35,475
+984
| +3% | +$14.7K | ﹤0.01% | 5242 |
|
|
2023
Q4 | $487K | Sell |
34,491
-187,376
| -84% | -$2.2M | ﹤0.01% | 5516 |
|
|
2023
Q3 | $2.29M | Buy |
221,867
+179,186
| +420% | +$2.4M | ﹤0.01% | 4120 |
|
|
2023
Q2 | $703K | Sell |
42,681
-649,545
| -94% | -$8.44M | ﹤0.01% | 5029 |
|
|
2023
Q1 | $6.34M | Buy |
692,226
+586,247
| +553% | +$4.82M | ﹤0.01% | 3299 |
|
|
2022
Q4 | $759K | Buy |
105,979
+35,853
| +51% | +$251K | ﹤0.01% | 5069 |
|
|
2022
Q3 | $351K | Sell |
70,126
-4,254
| -6% | -$23.4K | ﹤0.01% | 5635 |
|
|
2022
Q2 | $181K | Sell |
74,380
-162,951
| -69% | -$669K | ﹤0.01% | 6157 |
|
|
2022
Q1 | $1.62M | Buy |
237,331
+170,136
| +253% | +$1.17M | ﹤0.01% | 4798 |
|
|
2021
Q4 | $542K | Buy |
67,195
+39,397
| +142% | +$360K | ﹤0.01% | 5792 |
|
|
2021
Q3 | $273K | Sell |
27,798
-28,040
| -50% | -$221K | ﹤0.01% | 6078 |
|
|
2021
Q2 | $376K | Buy |
55,838
+14,425
| +35% | +$115K | ﹤0.01% | 5641 |
|
|
2021
Q1 | $374K | Buy |
41,413
+21,286
| +106% | +$172K | ﹤0.01% | 5598 |
|
|
2020
Q4 | $134K | Buy |
20,127
+627
| +3% | +$3.92K | ﹤0.01% | 5833 |
|
|
2020
Q3 | $98K | Buy |
19,500
+2,995
| +18% | +$21.8K | ﹤0.01% | 5715 |
|
|
2020
Q2 | $133K | Buy |
16,505
+13,505
| +450% | +$119K | ﹤0.01% | 5517 |
|
|
2020
Q1 | $24K | Buy |
+3,000
| New | +$23K | ﹤0.01% | 6112 |
|
|
2019
Q1 | – | Sell |
-4,819
| Closed | -$12K | – | 7089 |
|
|
2018
Q4 | $12K | Sell |
4,819
-5,785
| -55% | -$19.7K | ﹤0.01% | 6595 |
|
|
2018
Q3 | $46K | Buy |
10,604
+6,009
| +131% | +$32.4K | ﹤0.01% | 6238 |
|
|
2018
Q2 | $28K | Buy |
4,595
+1,041
| +29% | +$7.3K | ﹤0.01% | 6387 |
|
|
2018
Q1 | $25K | Sell |
3,554
-21,668
| -86% | -$191K | ﹤0.01% | 6309 |
|
|
2017
Q4 | $207K | Sell |
25,222
-19,227
| -43% | -$180K | ﹤0.01% | 5383 |
|
|
2017
Q3 | $466K | Buy |
44,449
+9,145
| +26% | +$87.3K | ﹤0.01% | 4994 |
|
|
2017
Q2 | $390K | Buy |
35,304
+2,551
| +8% | +$25.6K | ﹤0.01% | 5018 |
|
|
2017
Q1 | $317K | Buy |
32,753
+1,062
| +3% | +$10.6K | ﹤0.01% | 5108 |
|
|
2016
Q4 | $330K | Buy |
31,691
+2,315
| +8% | +$25.4K | ﹤0.01% | 5064 |
|
|
2016
Q3 | $364K | Sell |
29,376
-338
| -1% | -$4.42K | ﹤0.01% | 4827 |
|
|
2016
Q2 | $320K | Buy |
29,714
+3,993
| +16% | +$42.6K | ﹤0.01% | 4954 |
|
|
2016
Q1 | $284K | Sell |
25,721
-15,397
| -37% | -$153K | ﹤0.01% | 4940 |
|
|
2015
Q4 | $502K | Buy |
41,118
+15,454
| +60% | +$241K | ﹤0.01% | 4827 |
|
|
2015
Q3 | $418K | Buy |
25,664
+14,683
| +134% | +$323K | ﹤0.01% | 4927 |
|
|
2015
Q2 | $233K | Sell |
10,981
-7,941
| -42% | -$142K | ﹤0.01% | 5168 |
|
|
2015
Q1 | $340K | Buy |
18,922
+7,020
| +59% | +$110K | ﹤0.01% | 4576 |
|
|
2014
Q4 | $204K | Buy |
11,902
+11,147
| +1,476% | +$159K | ﹤0.01% | 5353 |
|
|
2014
Q3 | $11K | Buy |
755
+600
| +387% | +$8.62K | ﹤0.01% | 7279 |
|
|
2014
Q2 | $2K | Sell |
155
-600
| -79% | -$7.24K | ﹤0.01% | 7816 |
|
|
2014
Q1 | $10K | Sell |
755
-708
| -48% | -$7.59K | ﹤0.01% | 7186 |
|
|
2013
Q4 | $12K | Sell |
1,463
-1,192
| -45% | -$8.41K | ﹤0.01% | 7220 |
|
|
2013
Q3 | $17K | Buy |
2,655
+2,600
| +4,727% | +$16K | ﹤0.01% | 6947 |
|
|
2013
Q2 | $0 | Buy |
+55
| New | +$284 | ﹤0.01% | 7682 |
|
Other funds holding AVDL
Bank of America's AVDL Position: Q1 2026 in Review
Bank of America sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 606,106 shares — an estimated $13.1M sold.
Bank of America first reported a position in AVDL in Q2 2013 and held it in 47 quarters. The position peaked at $20.4M in Q3 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Bank of America reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 606,106 Avadel Pharmaceuticals shares in Q1 2026, an estimated $13.1M.
- Bank of America first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 47 quarters.
- Bank of America's Avadel Pharmaceuticals position peaked at $20.4M in Q3 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.